Jun Teruya

Jun Teruya

Auto-generated profile, based on publicly available information

Jun Teruya

Department of Pathology & Immunology, Baylor College of Medicine, Houston, Texas

Research Focus & Metrics

Academic Career Length

27Years (2000-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 September 2017 in Seminars in Thrombosis and Hemostasis
Verified
Journal Article
Closed access
PDF file
JTJames Thomas
James Thomas
VKVadim Kostousov
Vadim Kostousov
JTJun Teruya
Jun Teruya
Extracorporeal membrane oxygenation (ECMO) has been used for >40 years to support lung and heart failure; however, bleeding and thrombosis remain serious complications. The known etiologies of bleeding include heparin effect or overdose, coagulopathy, thrombocytopenia, platelet dysfunction, acquired von Willebrand syndrome, and hyperfibrinolysis. Bleeding sites may include cannula insertion sites, recent surgical incisions, vascular access sites, lung, gastrointestinal tract, mouth, nose, thoracic cavity, abdominal cavity, and brain. Massive bleeding in the brain, the most feared bleeding complication, can be rapidly fatal because it occurs in a rigid closed space, is difficult to drain, and cannot be stopped with direct pressure to the bleeding site. Pulmonary hemorrhage may cause irreversible lung damage. Management should be swift and precise to prevent fatal bleeding. In contrast, etiologies of thrombosis include high fibrinogen and factor VIII levels, heparin resistance, and platelet activation. Achieving the optimal anticoagulation balance to prevent bleeding and thrombosis in ECMO patients is extremely complex. Experts in hemostasis should be a part of an institutional ECMO team and continuously available for immediate management.

18 April 2022 in Journal of Thrombosis and Haemostasis
Verified
Journal Article
Open access
AMAdrian Minford
Adrian Minford
LBLeonardo R Brandão
Leonardo R Brandão
Maha OthmanMaha Othman
Maha Othman
CMChristoph Male
Christoph Male
RARezan Abdul‐Kadir
Rezan Abdul‐Kadir
JTJun Teruya
Jun Teruya
Severe congenital protein C deficiency (SCPCD) is rare and there is currently substantial variation in the management of this condition. A joint project by three Scientific and Standardization Committees of the ISTH: Plasma Coagulation Inhibitors, Pediatric/Neonatal Thrombosis and Hemostasis, and Women's Health Issues in Thrombosis and Hemostasis, was developed to review the current evidence and help guide on diagnosis and management of SCPCD. We provide a summary of the clinical presentations, differential diagnoses, appropriate investigations to confirm the diagnosis, approaches for management of the acute situation, and options for long-term management including subsequent pregnancies. We finally provide a set of recommendations to help in this regard.

7 February 2023 in Seminars in Thrombosis and Hemostasis
Verified
Journal Article
Closed access
PDF file
RBRobert Bartlett
Robert Bartlett
DADeepa J. Arachichilage
Deepa J. Arachichilage
MCMeera Chitlur
Meera Chitlur
SHShiu-Ki Rocky Hui
Shiu-Ki Rocky Hui
CNCindy Neunert
Cindy Neunert
JTJun Teruya
Jun Teruya
Extracorporeal membrane oxygenation (ECMO) was first started for humans in early 1970s by Robert Bartlett. Since its inception, there have been numerous challenges with extracorporeal circulation, such as coagulation and platelet activation, followed by consumption of coagulation factors and platelets, and biocompatibility of tubing, pump, and oxygenator. Unfractionated heparin (heparin hereafter) has historically been the defacto anticoagulant until recently. Also, coagulation monitoring was mainly based on bedside activated clotting time and activated partial thromboplastin time. In the past 50 years, the technology of ECMO has advanced tremendously, and thus, the survival rate has improved significantly. The indication for ECMO has also expanded. Among these are clinical conditions such as postcardiopulmonary bypass, sepsis, ECMO cardiopulmonary resuscitation, and even severe coronavirus disease 2019 (COVID-19). Not surprisingly, the number of ECMO cases has increased according to the Extracorporeal Life Support Organization Registry and prolonged ECMO support has become more prevalent. It is not uncommon for patients with COVID-19 to be on ECMO support for more than 1 year until recovery or lung transplant. With that being said, complications of bleeding, thrombosis, clot formation in the circuit, and intravascular hemolysis still remain and continue to be major challenges. Here, several clinical ECMO experts, including the “Father of ECMO”—Dr. Robert Bartlett, describe the history and advances of ECMO.

1 February 2020 in Thrombosis Research
Verified
Journal Article
Closed access
JTJun Teruya
Jun Teruya
LHLisa Hensch
Lisa Hensch
KBKaren Bruzdoski
Karen Bruzdoski
IAIki Adachi
Iki Adachi
SHShiu-Ki Rocky Hui
Shiu-Ki Rocky Hui
VKVadim Kostousov
Vadim Kostousov

1 June 2013 in American Journal of Clinical Pathology
Verified
Journal Article
Open access
PDF file
ESEsther P. Soundar
Esther P. Soundar
PJPurviben Jariwala
Purviben Jariwala
TNTrung C. Nguyen
Trung C. Nguyen
KEKaren W. Eldin
Karen W. Eldin
JTJun Teruya
Jun Teruya
Globally, adult intensive care units routinely use the International Society on Thrombosis and Haemostasis (ISTH) scoring system for identifying over

13 December 2019 in Seminars in Thrombosis and Hemostasis
Verified
Journal Article
Closed access
PDF file
ZFZhe Amy Fang
Zhe Amy Fang
ANAmir Hassan Navaei
Amir Hassan Navaei
LHLisa Hensch
Lisa Hensch
SHShiu-Ki Rocky Hui
Shiu-Ki Rocky Hui
JTJun Teruya
Jun Teruya
Cardiopulmonary bypass and extracorporeal membrane oxygenation (ECMO) cause hemostatic derangements that can predispose patients to both bleeding and thrombotic complications. Often, patients present for urgent surgery while taking medications including antiplatelet agents, vitamin K antagonists, and direct oral anticoagulants, which must be recognized, monitored, and managed. During extracorporeal circulation, appropriate anticoagulation, most commonly with heparin, is required to maintain blood flow and avoid thrombotic complications. However, anticoagulation and other effects of extracorporeal circuits can also have an undesired consequence of bleeding. Extracorporeal circulation leads to coagulopathy that may require therapy with blood products such as platelets, cryoprecipitate, and plasma in case a patient bleeds. Platelet dysfunction related to exposure to a foreign circuit is a primary concern, as is the development of acquired von Willebrand syndrome, which frequently remains undetected on routine testing. Hemorrhagic complications in ECMO, such as intracranial hemorrhage, pulmonary hemorrhage, and hemithorax, can occur. Hemostatic agents including antifibrinolytics, desmopressin, fibrinogen concentrates, and other factor concentrates may be needed to achieve hemostasis in these often-challenging patients. Managing bleeding on extracorporeal support requires careful monitoring and a thoughtful approach.